-- Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases -- ...

Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and ...

ALAMEDA, Calif. and TAIPEI, May 22, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) ...

ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024.

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and ...

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the launch of its comprehensive custom services for Beads-Based Cell Isolation utilizing Magnetic ...